Chan leaving. I do hope this isn't beginning of management exodus. If Arql was a start up, investors would be excited to have a company with a drug going into ph3 in major indication, followed by several significant ph2 trials in progress, about to file a new IND, a solid cash position and experienced management team...(at least they are now!). Would seem like attractive buyout candidate but big pharma will only buy "success" and we don't have that here...yet.